The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation

Journal of Hematology & Oncology

He Huang²  Chong Wang¹  Xing Zhang²  Haowen Xiao³  Limengmeng Wang² 

[1] Department of Haematology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, P R China;Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University, School of Medicine, No. 79 Qingchun Rd, Hangzhou 310003, Zhejiang Province, P R China;Department of Haematology, Guangzhou Liuhuaqiao Hospital, Guangzhou, Guangdong Province, P R China

关键词: Target therapy;    Hematopoietic stem cell transplantation;    Hematologic malignancies;    Shelterin;    Telomerase;    Telomere;   

Others  :  1144428
DOI  :  10.1186/s13045-014-0061-9

 received in 2014-06-10, accepted in 2014-08-06,  发布年份 2014

【 摘 要 】

Telomeres are specific nucleoprotein structures at the ends of eukaryotic chromosomes. Telomeres and telomere-associated proteins maintain genome stability by protecting the ends of chromosomes from fusion and degradation. In normal somatic cells, the length of the telomeres gradually becomes shortened with cell division. In tumor cells, the shortening of telomeres length is accelerated under the increased proliferation pressure. However, it will be maintained at an extremely short length as the result of activation of telomerase. Significantly shortened telomeres, activation of telomerase, and altered expression of telomere-associated proteins are common features of various hematologic malignancies and are related with progression or chemotherapy resistance in these diseases. In patients who have received hematopoietic stem cell transplantation (HSCT), the telomere length and the telomerase activity of the engrafted donor cells have a significant influence on HSCT outcomes. Transplantation-related factors should be taken into consideration because of their impacts on telomere homeostasis. As activation of telomerase is widespread in tumor cells, it has been employed as a target point in the treatment of neoplastic hematologic disorders. In this review, the characteristics and roles of telomeres and telomerase both in hematologic malignancies and in HSCT will be summarized. The current status of telomerase-targeted therapies utilized in the treatment of hematologic malignancies will also be reviewed.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Blackburn EH: Structure and function of telomeres. Nature 1991, 350:569-573.
• [2]Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T: Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503-504.
• [3]Olovnikov AM: A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973, 41:181-190.
• [4]Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
• [5]Takai H, Smogorzewska A, de Lange T: DNA damage foci at dysfunctional telomeres. Curr Biol 2003, 13:1549-1556.
• [6]Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
• [7]Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997, 3:1271-1274.
• [8]Greider CW, Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989, 337:331-337.
• [9]Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J: The RNA component of human telomerase. Science 1995, 269:1236-1241.
• [10]de Lange T: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005, 19:2100-2110.
• [11]Arat NÖ, Griffith JD: Human Rap1 interacts directly with telomeric DNA and regulates TRF2 localization at the telomere. J Biol Chem 2012, 287:41583-41594.
• [12]Chen Y, Yang Y, van Overbeek M, Donigian JR, Baciu P, de Lange T, Lei M: A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins. Science 2008, 319:1092-1096.
• [13]Ye JZ, Donigian JR, van Overbeek M, Loayza D, Luo Y, Krutchinsky AN, Chait BT, de Lange T: TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J Biol Chem 2004, 279:47264-47271.
• [14]Kendellen MF, Barrientos KS, Counter CM: POT1 association with TRF2 regulates telomere length. Mol Cell Biol 2009, 29:5611-5619.
• [15]Denchi EL, de Lange T: Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007, 448:1068-1071.
• [16]Wang Y, Shen MF, Chang S: Essential roles for Pot1b in HSC self-renewal and survival. Blood 2011, 118:6068-6077.
• [17]Ye JZ, Hockemeyer D, Krutchinsky AN, Loayza D, Hooper SM, Chait BT, de Lange T: POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev 2004, 18:1649-1654.
• [18]Nandakumar J, Bell CF, Weidenfeld I, Zaug AJ, Leinwand LA, Cech TR: The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature 2012, 492:285-289.
• [19]Capraro V, Zane L, Poncet D, Perol D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, Thomas X, El-Hamri M, Chelghoun Y, Michallet M, Wattel E, Mortreux F, Sibon D: Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol 2011, 39:195-202.e2.
• [20]Asfour IA, Fayek MH, El-Kourashy SA, Youssef SR, El-Gohary GM, Mohamed OF: Correlation of telomerase activity to apoptosis and survival in adult acute lymphoblastic leukemia: an Egyptian single-center study. Ann Hematol 2008, 87:213-221.
• [21]Wang Y, Fang M, Sun X, Sun J: Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival. Int J Lab Hematol 2010, 32:230-238.
• [22]Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW: Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res 1997, 3:619-625.
• [23]Shi JM, Huang H, Chen QF, Lin MF: A study of the relationship between expression level of TRF1 protein and telomerase activity in human acute leukemia. J Zhejiang Univ Sci B 2006, 7:154-158.
• [24]Ohyashiki JH, Hayashi S, Yahata N, Iwama H, Ando K, Tauchi T, Ohyashiki K: Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. Int J Oncol 2001, 18:593-598.
• [25]Yamada K, Yagihashi A, Yamada M, Asanuma K, Moriai R, Kobayashi D, Tsuji N, Watanabe N: Decreased gene expression for telomeric-repeat binding factors and TIN2 in malignant hematopoietic cells. Anticancer Res 2002, 22:1315-1320.
• [26]Kipps TJ: Chronic lymphocytic leukemia. Curr Opin Hematol 2000, 7:223-234.
• [27]Véronèse L, Tournilhac O, Callanan M, Prie N, Kwiatkowski F, Combes P, Chauvet M, Davi F, Gouas L, Verrelle P, Guièze R, Vago P, Bay JO, Tchirkov A: Telomeres and chromosomal instability in chronic lymphocytic leukemia. Leukemia 2013, 27:490-493.
• [28]Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM: Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia 2012, 26:826-830.
• [29]Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, Rosenquist R, Stilgenbauer S: Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008, 111:2246-2252.
• [30]Pozzo F, Dalbo M, Peragine N, Bomben R, Zucchetto A, Rossi F, Degan M, Rossi D, Chiarenza A, Grossi A, Di Raimondo F, Zaja F, Pozzato G, Secchiero P, Gaidano G, Del Poeta G, Zauli G, Fo ÀR, Guarini A, Gattei V: Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. J Hematol Oncol 2013, 6:83. BioMed Central Full Text
• [31]Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, Baerlocher GM, Röth A: Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 2011, 93:74-82.
• [32]Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S: Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995, 85:2315-2320.
• [33]Poncet D, Belleville A, t’kint de Roodenbeke C, Roborel de Climens A, Simon B, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E: Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 2008, 111:2388-2391.
• [34]Capraro V, Zane L, Poncet D, Perol D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, Thomas X, El-Hamri M, Chelghoun Y, Michallet M, Wattel E, Mortreux F, Sibon D: Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood 2011, 118:1316-1322.
• [35]Ramsay AJ, Quesada V, Foronda M, Conde L, Martínez-Trillos A, Villamor N, Rodríguez D, Kwarciak A, Garabaya C, Gallardo M, López-Guerra M, López-Guillermo A, Puente XS, Blasco MA, Campo E, López-Otín C: POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 2013, 45:526-530.
• [36]Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD: The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000, 275:24273-24278.
• [37]Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM: Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemiameasured by flow cytometry. Blood 2000, 95:1883-1890.
• [38]Drummond M, Lennard A, Brûmmendorf T, Holyoake T: Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma 2004, 45:1775-1781.
• [39]Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf TH: A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.Leukemia in press.
• [40]Bakalova R, Ohba H, Zhelev Z, Kubo T, Fujii M, Ishikawa M, Shinohara Y, Baba Y: Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. FEBS Lett 2004, 564:73-84.
• [41]Samassekou O, Li H, Hébert J, Ntwari A, Wang H, Cliché CG, Bouchard E, Huang S, Yan J: Chromosome arm-specific long telomeres: a new clonal event in primary chronic myelogenous leukemia cells. Neoplasia 2011, 13:550-560.
• [42]Samassekou O, Ntwari A, Hébert J, Yan J: Individual Telomere Lengths in Chronic Myeloid Leukemia. Neoplasia 2009, 11:1146-1154.
• [43]Samassekou O, Malina A, Hébert J, Yan J: Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia. J Hematol Oncol 2013, 6:26. BioMed Central Full Text
• [44]Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J: hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006, 20:671-679.
• [45]Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
• [46]Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF: Telomere length in myelodysplastic syndromes. Leuk Lymphoma 2011, 52:1528-1536.
• [47]Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK: Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia 2013, 27:897-906.
• [48]Marcondes AM, Bair S, Rabinovitch PS, Gooley T, Deeg HJ, Risques R: No telomere shortening in marrow stroma from patients with MDS. Ann Hematol 2009, 88:623-628.
• [49]Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, Göhring G: Telomere shortening and chromosomal instability in myelodysplastic syndromes. Gene Chromosome Canc 2010, 49:260-269.
• [50]Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, Toyama K: Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994, 54:3557-3560.
• [51]Ohyashiki JH, Iwama H, Yahata N, Ando K, Hayashi S, Shay JW, Ohyashiki K: Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999, 5:1155-1160.
• [52]Sieglová Z, Zilovcová S, Cermák J, Ríhová H, Brezinová D, Dvoráková R, Marková M, Maaloufová J, Sajdová J, Brezinová J, Zemanová Z, Michalová K: Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leuk Res 2004, 28:1013-1021.
• [53]Briatore F, Barrera G, Pizzimenti S, Toaldo C, Casa CD, Laurora S, Pettazzoni P, Dianzani MU, Ferrero D: Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther 2009, 8:883-889.
• [54]Gadji M, Adebayo Awe J, Rodrigues P, Kumar R, Houston DS, Klewes L, Dièye TN, Rego EM, Passetto RF, de Oliveira FM, Mai S: Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin Cancer Res 2012, 18:3293-3304.
• [55]Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM: Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994, 91:9857-9860.
• [56]Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA: Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 1997, 90:182-193.
• [57]Sekulovic S, Gylfadottir V, Vulto I, Gasparetto M, Even Y, Brookes C, Smith C, Eaves CJ, Lansdorp PM, Rossi FM, Humphries RK: Prolonged self-renewal activity unmasks telomerase control of telomere homeostasis and function of mouse hemopoietic stem cells. Blood 2011, 118:1766-1773.
• [58]Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW: Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
• [59]Ju Z, Jiang H, Jaworski M, Rathinam C, Gompf A, Klein C, Trumpp A, Rudolph KL: Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med 2007, 13:742-747.
• [60]Akiyama M, Asai O, Kuraishi Y, Urashima M, Hoshi Y, Sakamaki H, Yabe H, Furukawa T, Yamada O, Mizoguchi H, Yamada H: Shortening of telomere in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2000, 25:441-447.
• [61]Baerlocher GM, Rovó A, Müller A, Matthey S, Stern M, Halter J, Heim D, Rischewski J, Gratwohl A, Tichelli A: Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex. Blood 2009, 114:219-222.
• [62]Rufer N, Brümmendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E: Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood 2001, 97:575-577.
• [63]Imanishi T, Hano T, Nishio I: Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J Hypertens 2005, 23:1699-1706.
• [64]Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J: Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood 2011, 118:5021-5030.
• [65]Ricca I, Compagno M, Ladetto M, Rocci A, Dell’Aquila M, Omedè P, De Marco F, D’Antico S, Caracciolo D, Ferrero D, Carlo-Stella C, Tarella C: Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly-spaced high-dose chemotherapy courses with G-CSF. Leukemia 2005, 19:644-651.
• [66]Ruella M, Rocci A, Ricca I, Carniti C, Bodoni CL, Ladetto M, Caracciolo D, Boccadoro M, Carlo-Stella C, Corradini P, Tarella C: Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplant 2010, 45:505-512.
• [67]Mangerini R, Lanino E, Terranova P, Faraci M, Pistillo MP, Gaetani GF, Ferraris AM: Telomere length of donors influences granulocyte recovery in children after hematopoietic stem cell transplantation. Ann Hematol 2009, 88:1029-1031.
• [68]Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R: Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009, 27:791-798.
• [69]Peffault de Latour R, Calado RT, Busson M, Abrams J, Adoui N, Robin M, Larghero J, Dhedin N, Xhaard A, Clave E, Charron D, Toubert A, Loiseau P, Socié G, Young NS: Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Blood 2012, 120:3353-3359.
• [70]Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A: Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007, 35:297-304.
• [71]Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J: Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 2014, 15:829-840.
• [72]Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C: A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 2013, 14:461-465.
• [73]Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis C, Cordopatis P, Kosmatopoulos K, Mavroudis D: Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann Oncol 2012, 23:442-449.
• [74]Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D: Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007, 25:2727-2734.
• [75]Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J: Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002, 62:5041-5048.
• [76]DiPersio JF, Collins RH Jr, Blum W, Devetten MP, Stiff P, Elias L, Reddy A, Smith JA, Khoury HJ: Immune responses in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase catalytic subunit hTERT [abstract]. Blood 2009, 114:633.
• [77]Khoury HJ, Collins RH Jr, Blum W, Maness L, Stiff P, Kelsey SM, Reddy A, Smith JA, DiPersio JF: Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML) [abstract]. Blood 2010, 116:2190.
• [78]Lin C, Damle RN, Chiorazzi N, Chin AC: GRN163L inhibits telomerase activity in B-CLL cells [Abstract]. Blood 2005, 106:5041.
• [79]Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, Huff CA, Jones RJ, Matsui W: Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. Plos ONE 2010, 5:e12487.
• [80]Chanan-Khan AA, Munshi NC, Hussein MA, Elias L, Benedetti F, Smith J, Khor SP, Huff CA: Results of a phase I study of GRN163L, a direct inhibitor of telomerase, in patients with relapsed and refractory multiple myeloma (MM). Blood 2008, 112:1263.
• [81]Tefferi A, Begna K, Laborde RR, Patnaik MM, Lasho TL, Zblewski D, Finke C, Schimek L, LaPlant BR, Hanson CA, Stuart MJ, Pardanani A: Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in Myelofibrosis and reversal of bone marrow fibrosis [Abstract]. Blood 2013, 122:662.
• [82]Bashash D, Ghaffari SH, Zaker F, Kazerani M, Hezave K, Hassani S, Rostami M, Alimoghaddam K, Ghavamzadeh A: BIBR1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL. Anticancer Agents Med Chem 2013, 13:1115-1125.
• [83]Bashash D, Ghaffari SH, Mirzaee R, Alimoghaddam K, Ghavamzadeh A: Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells. Leuk Lymphoma 2013, 54:561-568.
• [84]Bashash D, Ghaffari SH, Zaker F, Hezave K, Kazerani M, Ghavamzadeh A, Alimoghaddam K, Mosavi SA, Gharehbaghian A, Vossough P: Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription. Cancer Invest 2012, 30:57-64.
• [85]Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf TH: Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. Exp Hematol 2011, 39:66-76.
• [86]Chai JH, Zhang Y, Tan WH, Chng WJ, Li B, Wang X: Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. BMC Cancer 2011, 11:512. BioMed Central Full Text
• [87]Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005, 92:1881-1891.
• [88]Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G: Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp Hematol 2010, 38:27-37.
• [89]Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010, 3:47. BioMed Central Full Text
• [90]Shapira S, Granot G, Mor-Tzuntz R, Raanani P, Uziel O, Lahav M, Shpilberg O: Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer Lett 2012, 323:223-231.
• [91]Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
• [92]Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 2010, 3:28. BioMed Central Full Text
• [93]Ghaffari SH, Momeny M, Bashash D, Mirzaei R, Ghavamzadeh A, Alimoghaddam K: Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkbeta-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 2012, 17:198-206.
• [94]Xu D, Erickson S, Szeps M, Gruber A, Sangfelt O, Einhorn S, Pisa P, Grandér D: Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000, 96:4313-4318.
• [95]Lindkvist A, Ivarsson K, Jernberg-Wiklund H, Paulsson-Karlsson Y: Interferon-induced sensitization to apoptosis is associated with repressed transcriptional activity of the hTERT promoter in multiple myeloma. Biochem Biophys Res Commun 2006, 341:1141-1148.